Startups, Venture

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

The biotech news these days is dominated by startups and big money, but the cautionary tales still keep coming. 

XTuit Pharmaceuticals had banked on the ideas of some of the most prominent scientists engaged in drug development, relied on a seasoned biotech exec as CEO and had solid backing from some marquee investors like Polaris and NEA.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->